Yosemite Management

Yosemite Management

Yosemite Management operates out of Menlo Park with additional presences in San Francisco, Greenwich, and Riyadh. The firm orients its entire investment thesis around a single, publicly stated mission: rendering cancer a non-lethal disease. This biomedical focus, unusual in its concentration, frames every capital allocation decision. The firm's geographic split between US innovation hubs and Gulf-based capital sources suggests a deliberate pairing of deep-tech origination with sovereign-linked or ultra-high-net-worth limited partners. Yosemite's strategy is strictly venture capital, targeting the translational gap between academic discovery and clinical application. The firm invests from seed through late-stage expansion, concentrating on biotech platforms where computational biology, AI-driven drug discovery, and novel therapeutic modalities converge. The asset-class mix is pure private equity, with no indication of hedge fund, credit, or real asset sleeves. Yosemite's preference appears to be direct startup equity, typical of an early-stage life-science venture firm. The dual-coastal US footprint and the Riyadh office imply a deal-sourcing model that bridges Silicon Valley's startup density with the Middle East's growing appetite for healthcare innovation investments. The firm keeps team size and total capital deployment undisclosed. In recent years, a growing number of single-purpose venture firms have emerged in oncology — a structural shift Yosemite reflects, though its specific fund vintage, limited partner composition, and assets under management remain opaque. The Riyadh office signals a capital formation link to the Gulf, an increasingly active region for healthcare and biotech allocations. Yosemite's stark structural differentiator is its mandate concentration. While most venture firms spread exposure across enterprise software, fintech, and consumer, Yosemite's entire existence is bound to a single therapeutic outcome. This creates a binary risk-reward profile for allocators: the firm's value hinges entirely on oncology's scientific and regulatory trajectory. The lack of a diversified sector strategy, combined with an undisclosed fund structure, makes Yosemite a high-conviction, single-thesis vehicle — an architecture far removed from a generalist multi-family office or broad venture platform.